Alto Neuroscience Inc. (ANRO)
NYSE: ANRO
· Real-Time Price · USD
2.57
0.19 (8.21%)
At close: Jun 06, 2025, 3:59 PM
2.58
0.39%
After-hours: Jun 06, 2025, 07:55 PM EDT
8.21% (1D)
| Bid | 2.55 |
| Market Cap | 69.58M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -63.18M |
| EPS (ttm) | -2.3 |
| PE Ratio (ttm) | -1.12 |
| Forward PE | -0.86 |
| Analyst | Buy |
| Ask | 2.58 |
| Volume | 242,627 |
| Avg. Volume (20D) | 259,811 |
| Open | 2.42 |
| Previous Close | 2.38 |
| Day's Range | 2.40 - 2.60 |
| 52-Week Range | 1.60 - 17.55 |
| Beta | 1.93 |
About ANRO
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol ANRO
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for ANRO stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts2 months ago
+25.56%
Alto Neuroscience shares are trading higher after ...
Unlock content with
Pro Subscription
7 months ago
-69.99%
Alto Neuroscience shares are trading lower after the company announced topline results from a Phase 2b trial evaluating ALTO-100 as a treatment for major depressed disorder did not meet its primary endpoint.
1 month ago · businesswire.com
Alto Neuroscience to Participate in the JonesResearch Virtual CNS DayMOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $ANRO #PrecisionPsychiatry--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel pre...
